MD MEDNAX Inc.

MEDNAX Announces Acquisition of Leading Texas Radiology Practice

MEDNAX, Inc. (NYSE:MD), today announced the acquisition of Women’s Radiology Associates, LLP, a private radiology physician group based in Houston. The practice will integrate with Synergy Radiology Associates, a MEDNAX-affiliated physician practice, also based in Houston.

This marks the Company’s sixth radiology services practice acquisition, further establishing MEDNAX as the partner of choice for leading radiology practices and physician services by combining physician excellence with world-class technological capabilities.

Women’s Radiology Associates was established in 1974 by physicians who pioneered fetal growth assessment research, a groundbreaking approach to assess in-utero fetal growth. Comprising six board-certified radiologists, the group provides a broad range of inpatient and outpatient diagnostic imaging services at The Woman’s Hospital of Texas. Specialized services include mammography, obstetric sonography, gynecological sonography, computed tomography and neonatal imaging.

“Our highly experienced radiologists are recognized experts in women's imaging, and we are proud to have served the community for the past 40 years as the only local radiology group exclusively performing women's and neonatal imaging at The Woman’s Hospital of Texas,” said Yogesh P. Shah, M.D., Managing Partner of Women’s Radiology Associates and Chairman of the Department of Radiology at The Woman’s Hospital of Texas. “We look forward to sharing this expertise with the greater MEDNAX Radiology group while continuing to provide the high quality, specialized patient care we are known for.”

“Women’s Radiology Associates is a welcome addition to MEDNAX Radiology as we continue to expand our radiology physician services and enhance our integrated physician services offering,” said Walid K. Adham, M.D., Practice Chair of Synergy Radiology Associates. “The team will add a wealth of specialized expertise in women’s and neonatal imaging, and Synergy is eager to continue to build upon the tradition of outstanding clinical care provided by Dr. Shah and team at The Woman’s Hospital of Texas.”

Upon completion of the transaction, MEDNAX’s affiliated radiologists will read more than 11 million studies annually.

This was a cash transaction and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

With this acquisition, five physician group practices have become part of MEDNAX in 2018.

ABOUT MEDNAX

MEDNAX, Inc. is a national health solutions partner based in Sunrise, Fla. comprised of the nation's leading providers of physician services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telemedicine to enhance patient outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional corporations, MEDNAX provides services through a network of approximately 4,100 physicians in all 50 states and Puerto Rico. In addition to its national physician network, MEDNAX provides services to healthcare facilities and physicians in over 40 states through two complementary businesses, consisting of a revenue cycle management company and a consulting services company. Additional information is available at www.mednax.com.

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe”, “hope”, “may”, “anticipate”, “should”, “intend”, “plan”, “will”, “expect”, “estimate”, “project”, “positioned”, “strategy” and similar expressions, and are based on assumptions and assessments made by MEDNAX’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in MEDNAX’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well MEDNAX’s current reports on Form 8-K, filed with the Securities and Exchange Commission.

EN
24/04/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MEDNAX Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Pediatrix Medical Group, Inc.: 1 director

A director at Pediatrix Medical Group, Inc. sold/sold after exercising options 33,000 shares at 13.260USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company...

Mednax, Inc.: Covenant Quality Post-Sale Snapshot: $400m 5.375% Senior...

Mednax. Inc.’s covenant package provides lower-tier HY-Lite protection, reflecting a covenant quality score of 5.00.

Mednax, Inc.: Update following upgrade of CFR to Ba3

Our credit view of this issuer reflects its high leverage, offset by its strong competitive position.

Moody's upgrades Mednax's CFR to Ba3; rates new unsecured notes Ba3, o...

Rating Action: Moody's upgrades Mednax's CFR to Ba3; rates new unsecured notes Ba3, outlook stable. Global Credit Research- 01 Feb 2022. New York, February 01, 2022-- Moody's Investors Service upgraded Mednax, Inc.' s Corporate Family Rating to Ba3 from B1 and Probability of Default Rating to Ba3-PD from B1-PD.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch